چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| مهدی یوسفی | دوم |
| امیر ولیزاده دیزجیکان | اول |
| عنوان | متن |
|---|---|
| کلمات کلیدی | Tacrolimus, Recurrent implantation failure, Immunologic factors, Pregnancy outcome |
| خلاصه مقاله | Recurrent implantation failure (RIF) is a challenging condition in assisted reproductive technology (ART) treatments, characterized by the inability to achieve a successful pregnancy despite repeated embryo transfers. It is known that immunologic factors play a crucial role in RIF, leading to impaired embryo implantation and early pregnancy loss. Tacrolimus, a potent immunosuppressant, has been increasingly utilized to manage various immune-mediated disorders. However, its role in improving pregnancy outcomes in women with RIF associated with immunologic factors remains unclear. Therefore, this study aimed to investigate the effects of Tacrolimus on pregnancy outcomes in this specific patient population. This prospective, randomized, double-blind, placebo-controlled trial was conducted at a reproductive medicine center. One hundred women diagnosed with RIF associated with immunologic factors were recruited and randomly allocated to either the Tacrolimus or the control group. The Tacrolimus group received Tacrolimus treatment orally, starting from the day of embryo transfer until 10 weeks of gestation, while the control group received a placebo with the same administration schedule. Demographic characteristics, reproductive history, and immunologic profiles were recorded. Pregnancy outcomes, including clinical pregnancy rate, live birth rate, and miscarriage rate, were assessed and compared between the two groups using appropriate statistical analysis. Among the 100 patients enrolled in the study, 50 were assigned to the Tacrolimus group, and the remaining 50 were assigned to the control group. The demographic characteristics and reproductive history were comparable between the two groups. In terms of pregnancy outcomes, the Tacrolimus group showed a significantly higher clinical pregnancy rate (p<0.05), live birth rate (p<0.01), and a lower miscarriage rate (p<0.01) compared to the control group. These findings indicate a positive effect of Tacrolimus on pregnancy outcomes in women with RIF associated with immunologic factors. The results of this study demonstrate that Tacrolimus administration in women with RIF associated with immunologic factors significantly improves pregnancy outcomes. The immunosuppressive properties of Tacrolimus may help alleviate the immune dysregulation observed in these patients, enhancing embryo implantation and reducing the risk of pregnancy loss. However, further research is warranted to elucidate the underlying mechanisms and optimize the dosage and duration of Tacrolimus treatment. Nonetheless, these findings provide important insights into the potential therapeutic role of Tacrolimus in improving reproductive outcomes in this specific patient population. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| photo_6041700323594190296_y.jpg | 1402/09/14 | 42339 | دانلود |
| bill.JPG | 1402/09/14 | 78668 | دانلود |
| 28_425_090db5c5e7e282f1b98c246d5b82da66.jpg | 1402/09/14 | 279860 | دانلود |
| 26.pdf | 1402/09/14 | 410083 | دانلود |
| art.JPG | 1402/09/14 | 58611 | دانلود |
| Arcims24AbstractsFinal (2)-102.pdf | 1402/12/10 | 145534 | دانلود |
